iCAD (NASDAQ:ICAD) Announces Earnings Results

iCAD (NASDAQ:ICAD) announced its quarterly earnings data on Wednesday. The technology company reported ($0.03) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.05) by $0.02, Zacks reports. iCAD had a negative net margin of 17.81% and a negative return on equity of 15.65%. The firm had revenue of $5.41 million during the quarter, compared to analyst estimates of $4.72 million.

iCAD Price Performance

Shares of ICAD stock opened at $2.09 on Friday. The business has a 50-day moving average of $2.65 and a 200 day moving average of $2.05. iCAD has a 1-year low of $1.18 and a 1-year high of $3.78. The stock has a market capitalization of $55.47 million, a PE ratio of -16.08 and a beta of 1.95.

Analyst Ratings Changes

Separately, StockNews.com cut shares of iCAD from a “hold” rating to a “sell” rating in a research report on Tuesday.

iCAD Company Profile

iCAD, Inc engages in the provision of cancer detection and therapy solutions in the United States. It operates through two segments, Detection and Therapy. The company provides ProFound AI for digital breast tomosynthesis and 2D mammography; PowerLook, a density assessment solution; and ProFound Risk, a breast cancer risk analysis.